At Work With: Ryan Mason

Ryan Mason
Ryan Mason
RYAN MASON
Vice President, Strategy & Creative, closerlook, inc.

What was your biggest break?
closerlook gave me the opportunity to enroll in graduate marketing courses at the University of Chicago.   

What's the best and/or worst part of your job?
The best parts of my job are:
1. Creating the environment in which talented, thoughtful, motivated professionals can do their best work.
2. Figuring out how to do the work while doing the work.  

How long is a typical meeting with clients?
We take client relationships seriously. We aim to make our meetings multi-day affairs with great food, costumes, acrobats and drink. With the pace of business today, sometimes we talk for an hour over a web conference, too.    

What books are you reading?
I re-read A Technique for Producing Ideas by James Webb Young every year. I also consume all the media created for well-educated, vain, Gen-X, urban creative professionals that I can.

What was your greatest professional challenge?
Creating the ability to repeatedly produce strong work—rooted in strategy and reflective of a creative aesthetic—before we were known for doing so.

You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.